KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Cash & Equivalents (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Cash & Equivalents for 16 consecutive years, with $4.6 billion as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Cash & Equivalents fell 24.48% year-over-year to $4.6 billion, compared with a TTM value of $4.6 billion through Sep 2024, down 24.48%, and an annual FY2023 reading of $8.1 billion, down 5.24% over the prior year.
  • Cash & Equivalents was $4.6 billion for Q3 2024 at Thermo Fisher Scientific, down from $7.1 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $12.0 billion in Q4 2021 and bottomed at $1.9 billion in Q3 2022.
  • Average Cash & Equivalents over 5 years is $5.8 billion, with a median of $5.6 billion recorded in 2021.
  • The sharpest move saw Cash & Equivalents soared 492.3% in 2020, then plummeted 75.73% in 2022.
  • Year by year, Cash & Equivalents stood at $10.3 billion in 2020, then crashed by 56.64% to $4.5 billion in 2021, then skyrocketed by 90.4% to $8.5 billion in 2022, then fell by 5.24% to $8.1 billion in 2023, then plummeted by 42.49% to $4.6 billion in 2024.
  • Business Quant data shows Cash & Equivalents for TMO at $4.6 billion in Q3 2024, $7.1 billion in Q2 2024, and $5.5 billion in Q1 2024.